Kompass Diagnostics today announced that it has been selected as a finalist in the 2026 ADLM Disruptive Technology Award Competition, presented by the Association for Diagnostics and Laboratory Medicine (ADLM), the world’s largest conference dedicated to laboratory medicine and diagnostics.
Kompass is one of only three companies selected to present its technology live at ADLM 2026 on July 27 in Anaheim, California, before an audience of laboratory medicine professionals, clinicians, researchers, and industry leaders from around the world. The company will also exhibit in the ADLM Disruptive Technology Zone from July 28–30.
The ADLM Disruptive Technology Award recognizes emerging technologies with the potential to significantly advance laboratory medicine through scientific innovation, clinical impact, and commercial potential. Finalists are selected through a competitive review process by leaders across the diagnostics industry.
Kompass was recognized for its Electrical Transduction Architecture (ETA), a semiconductor-native platform designed to fundamentally rethink how biological information is converted into digital data.
Today, nearly every diagnostic instrument relies on optical detection, using lasers, filters, lenses, photodetectors, and other complex optical components to convert biological events into digital information. While these systems have enabled modern laboratory medicine, they remain expensive, centralized, and difficult to deploy beyond traditional laboratory settings.
ETA takes a fundamentally different approach. Instead of converting biology into light before measurement, ETA converts biological events directly into electrical signals using semiconductor technology. By bypassing the optical chain, the platform has the potential to simplify instrumentation, reduce costs, and enable laboratory-quality biomarker testing in smaller, more accessible formats.
Kompass believes diagnostics is approaching a technological inflection point similar to the transition from film to digital imaging. Digital cameras did not transform photography simply because they produced better images—they transformed photography because images became electronic information that could be processed, stored, transmitted, and integrated into the broader digital ecosystem. Kompass believes healthcare now requires a similar transition, where biological information becomes semiconductor-native and digitally observable at scale.
“Healthcare has not yet experienced the same data revolution that transformed industries like communications, commerce, and transportation,” said Mingoo Kim, Co-founder and CEO of Kompass Diagnostics. “We believe the future depends on making biology dramatically easier to measure. ETA is our attempt to build that foundational hardware layer by converting biochemistry directly into electrical information.”
Kompass is intentionally introducing ETA through a CLIA-waived point-of-care hormone testing platform for fertility clinics. Fertility medicine provides an ideal proving ground: hormone measurements are performed frequently, turnaround time directly influences clinical decision-making, and laboratory-quality performance is essential at the point of care.
Beginning in the clinical setting allows Kompass to validate a fundamentally new transduction architecture under real-world conditions while delivering immediate value to providers and patients. The company views this clinical-first strategy as the foundation for its broader vision of bringing true clinical-grade diagnostics directly into consumers’ hands.
“We believe laboratory-quality biomarker testing should ultimately become as accessible as taking a photograph with your smartphone,” said Kim. "But transformational technologies earn trust one step at a time. We start in the clinic because that’s where we can demonstrate analytical performance, workflow integration, and reliability. Once we’ve proven the platform there, we’re positioned to bring true clinical-grade diagnostics into the hands of consumers.”
Kompass believes the long-term opportunity extends far beyond individual diagnostic tests. By making biology easier to measure and digitize, the company aims to build a semiconductor-native infrastructure that enables biomarker data to become vastly more accessible.
